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Table 1. Adjusted FXIII levels in different groups of male and female patients.*
Patient groups CS–MI– CS–MI+ CS+MI– CS+MI+
(female/male) (178/124) (11/23) (112/200) (76/231)
Mean (95% CI) Mean (95% CI) p value* Mean (95% CI) p value* Mean (95% CI) p value*
FXIII activity (%)
total 103 (100-106) 106 (98-114) 0.45 101 (98-104) 0.19 102 (99-105) 0.59
female 101 (96-107) 112 (97-126) 0.16 98 (92-105) 0.28 107 (100-115)° 0.09
male 103 (99-107) 103 (94-113) 0.88 101 (97-105) 0.55 101 (97-104) 0.39
FXIII antigen (mg/L)
total 22.9 (22.2-23.6) 24.0 (22.2-25.8) 0.24 22.2 (21.5-23.0) 0.13 22.6 (21.9-23.3) 0.46
female 22.6 (21.4-23.7) 25.1(21.7-28.5) 0.13 22.1 (20.6-23.5) 0.46 24.1 (22.4-25.8)# 0.04
male 23.0 (22.0-24.0) 23.5 (21.3-25.7) 0.68 22.2 (21.4-23.1) 0.21 22.2 (21.4-23.0) 0.16
Values represent adjusted mean plasma FXIII activity or antigen (95% confidence interval). FXIII activity is expressed as percentage of average normal. The median age
of females and males was 57.7 years (range: 31-82), and 56.6 years (range: 30-88), respectively. The significance of differences in mean FXIII values between the clinical
control and different patient groups was tested by analysis of variance (ANOVA). When one-way ANOVA indicated a significant difference, post-hoc pair-wise
comparisons were made using the LSD (least significant difference) test. CS+ and CS–: patients with and without significant coronary sclerosis, respectively; MI+ and MI–:
patients with and without a history of myocardial infarction, respectively. *Compared to the respective clinical control (CS–MI–) subgroup. °p=0.02 for comparison with
females in the CS+MI– group. #p=0.02 for the comparison with females in the CS+MI– group. Statistical analyses were performed using the Statistical Package for Social
Sciences (SPSS 11.5).
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Elevated factor XIII level and the risk of
myocardial infarction in women
Factor XIII (FXIII) activity and antigen levels
were determined in 955 patients investigated by
coronary angiography. Patients were sub-grouped
according to the presence or absence of coronary
sclerosis (CS+, CS–) and a positive history of
myocardial infarction (MI+, MI–). In females, but not
in males, adjusted FXIII activity and antigen levels
were significantly elevated in the CS+MI+ group
compared to in the CS+MI– group. FXIII levels in the
upper tertile were associated with significantly
increased risk of MI in females, but not in males. 
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Coronary artery disease (CAD) is a major health issue
in both women and men, however the time of its onset,
the course of the disease the presentation of clinical
symptoms and the response to therapy show gender-spe-
cific features.1,2 Fibrinogen and the fibrinolytic inhibitor
PAI-1 are the most well-established hemostatic risk fac-
tors for CAD and gender-related differences could also be
demonstrated concerning the effects of these risk fac-
tors.3,4 Factor XIII (FXIII) is intimately related to fibrinogen
and is a key factor in the regulation of fibrinolysis.5 Its
active form (FXIIIa) cross-links fibrin α- and γ-chains and
covalently attaches α2-plasmin inhibitor to fibrin. In this
way, FXIIIa mechanically stabilizes fibrin and protects it
from the fibrinolytic system. 
In the present study FXIII activity and antigen levels
were measured in a large number of patients with sus-
pected CAD using REA-chrom FXIII and R-ELISA FXIII
(Reanal) reagent kits, respectively.6,7 Nine hundred and
fifty-five consecutive patients admitted for coronary
angiography were recruited for the study. Patients with
≥50% stenosis in a major coronary artery or in one of its
branches were defined as having coronary sclerosis (CS+).
The diagnosis of myocardial infarction (MI+) was estab-
lished at the time of its onset according to WHO criteria.
At least 3 months were allowed to elapse between the
MI and the time of obtaining blood samples for analysis.
Patients without significant coronary stenosis and with
no history of MI were considered as the clinical control
group (CS–MI–) to which subgroups of patients with CS
and/or MI (CS+MI–, CS–MI+ and CS+MI+) were compared.
Ethical approval was obtained from the University of
Debrecen Ethics Committee, and the subjects gave
informed consent.
Serum cholesterol, LDL-cholesterol, HDL-cholesterol,
triglyceride, apoAI, apoB, lipoprotein (a), homocysteine
and fibrinogen were determined by routine laboratory
methods. Age, current smoking, body mass index, and
the presence of hypertension and diabetes mellitus were
recorded. The median age of the women was 57.7 years;
91.7% were menopausal and they were not on hormon-
al replacement therapy. 
Neither FXIII activity nor FXIII antigen levels of the
clinical controls differed significantly from those meas-
ured in the healthy reference population. Multiple linear
regression demonstrated that gender, smoking, choles-
terol and fibrinogen levels were independently associat-
ed with FXIII activity and FXIII antigen levels, and mean
FXIII levels adjusted for these parameters were used in
the analysis.
CS and/or MI did not influence adjusted FXIII levels in
either the overall population or in the male patients
(Table 1). The relationship between CAD and plasma
FXIII levels has been investigated in only a few studies
including relatively low numbers of males or predomi-
nantly male patients.8-10 The basically negative outcome
of these studies agrees well with the results of the pres-
ent study. The effect of CS or MI on FXIII levels in
females has not been addressed previously. CS alone did
not have an effect in females, either. However, when CS+
females with and without a history of MI were com-
pared, statistically significant elevations of both FXIII
activity and antigen levels were observed in the MI+
group. The comparison of CS+MI+ group to clinical con-
trols also revealed a significant elevation of FXIII antigen.
Given the small number of patients, the difference
between the group with the highest FXIII levels (CS–MI+)
Table 2. The effect of FXIII levels in the upper tertile on the risk of coronary sclerosis or myocardial infarction in males and females. 
Patient groups CS+MI– versus CS–MI– CS–MI+ versus CS–MI– CS+MI+ versus CS–MI– CS+MI+ versus CS+MI–
OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
FXIII activity
female 1.553 (0.913-2.642) 0.10 2.437 (0.648-9.138) 0.19 3.091 (1.648-5.798) <0.001 1.873 (1.015-3.458) 0.04
male 1.401 (0.842-2.332) 0.19 1.356 (0.528-3.482) 0.53 1.015 (0.608-1.694) 0.96 0.719 (0.476-1.086) 0.12
FXIII antigen
female 1.286 (0.752-2.199) 0.36 2.287 (0.629-8.321) 0.21 2.346 (1.269-4.336) 0.007 1.999 (1.051-3.765) 0.03
male 0.757 (0.459-1.248) 0.28 1.196 (0.479-2.988) 0.70 0.753 (0.457-1.240) 0.27 0.918 (0.602-1.398) 0.69
CS+ and CS–: patients with and without significant coronary sclerosis, respectively; MI+ and M–: patients with and without a history of myocardial infarction,
respectively. OR values represent adjusted odds ratios (95% confidence interval) which were computed from the corresponding regression coefficients in the logistic
regression model that included parameters significantly associated with the presence of CS and/or MI. Statistical analyses were performed using the Statistical Package for
Social Sciences (SPSS 11.5). 
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and clinical controls did not reach the level of statistical
significance. 
FXIII levels in the upper tertile (FXIII activity > 110%,
FXIII antigen > 24.1 mg/L) did not confer a significant risk
of CS to either men or  women without a history of MI
(CS+MI– versus CS–MI–) (Table 2). In contrast to the
respective male subgroup, when the female CS+MI+ sub-
group was compared to female clinical controls high odds
ratios with high statistical significance were calculated.
To separate the effect of elevated FXIII level on the risk of
CS and MI even more clearly, subgroups of patients with
and without a history of MI, but with significant CS were
compared (CS+MI+ versus CS+MI–). Elevated FXIII levels
were associated with a significantly increased risk of MI
in women, but not in men. 
On the basis of these results, elevated FXIII can be
regarded as a gender (female)-specific risk factor for MI,
and FXIII determination could be a candidate for inclu-
sion in the risk stratification for women. By preventing
plasmin-induced degradation of fibrin, elevated FXIII lev-
els could play a role in sustaining newly formed throm-
bus in coronary arteries. Although it remains to be seen
why such a mechanism operates only in women, the
results support the view that the clotting system plays a
more prominent role in the development of MI in females
than in males.
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